ABSTRACT Pulmonary arterial hypertension (PAH) is a progressive cardiopulmonary disease in which right ventricular (RV) failure is the leading cause of mortality. Although current vasodilator therapies improve pulmonary hemodynamics, they do not consistently reverse the structural, metabolic, and inflammatory maladaptive changes of the RV. Traditional Chinese medicine (TCM) and natural products, characterized by multi‐target and system‐oriented actions, may regulate metabolic pathways involved in RV maladaptation and offer potential complementary therapeutic strategies for PAH. Integrating traditional medical knowledge with modern systems biology and precision medicine approaches may further facilitate the development of personalized therapeutic strategies. However, rigorous evaluation of pharmacokinetics, safety, and herb–drug interactions, along with standardized clinical evaluation is essential to facilitate clinical translation. Together, these advances highlight the potential of natural products and TCM to improve RV function and advance mechanism‐based, personalized cardiometabolic therapy for PAH.
Wu et al. (Thu,) studied this question.